Aytu BioScience announces $8.6M public offering of stock and warrants

Aytu BioScience announces $8.6M public offering of stock and warrants

ENGLEWOOD -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced it has priced... Read More

Friday October 28, 2016 0 comments Tags: Englewood, Aytu BioScience

Aytu BioScience announces $10.5M stock agreement

Aytu BioScience announces $10.5M stock agreement

ENGLEWOOD -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced it has entered... Read More

Thursday July 28, 2016 0 comments Tags: Englewood, Aytu BioScience, Josh Disbrow, Natesto

Aytu BioScience announces study demonstrating utility of male infertility product

Aytu BioScience announces study demonstrating utility of male infertility product

ENGLEWOOD -- Aytu BioScience, Inc .(OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced the publication... Read More

Thursday July 21, 2016 0 comments Tags: Englewood, Aytu BioScience, Josh Disbrow, MiOXSYS

Aytu BioScience provides update on Natesto launch

Aytu BioScience provides update on Natesto launch

ENGLEWOOD -- Aytu BioScience Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, announced an update on the... Read More

Wednesday July 6, 2016 0 comments Tags: Englewood, Aytu BioScience, Natesto, Acerus Pharma, Jonathan McGrael, Josh Disbrow

Aytu BioScience announces European distribution for MiOXSYS infertility drug

Aytu BioScience announces European distribution for MiOXSYS infertility drug

ENGLEWOOD -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced it has entered... Read More

Tuesday June 14, 2016 0 comments Tags: Englewood, Aytu BioScience, Josh Disbrow, MiOXSYS

Aytu BioScience study demonstrates expanded utility of MiOXSYS for assessing oxidative stress as male infertility marker

Aytu BioScience study demonstrates expanded utility of MiOXSYS for assessing oxidative stress as male infertility marker

ENGLEWOOD -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced new clinical... Read More

Tuesday May 10, 2016 0 comments Tags: Englewood, Aytu BioScience, Ashok Agarwal, Josh Disbrow, MiOXSYS

Aytu BioScience offering 18.75M shares to raise $7.5M

Aytu BioScience offering 18.75M shares to raise $7.5M

ENGLEWOOD -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on commercializing novel products in the field of urology, today announced it has priced an... Read More

Tuesday May 3, 2016 0 comments Tags: Aytu BioScience, Englewood, Natesto, MiOXSYS, ProstaScint, Primsol

Aytu Bioscience acquires rights to Natesto drug

Aytu Bioscience acquires rights to Natesto drug

ENGLEWOOD -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on commercializing novel products in the field of urology, today announced the exclusive licensing... Read More

Monday April 25, 2016 0 comments Tags: Aytu BioScience, Englewood, Natesto, Acerus Pharma, Josh Disbrow, Tom Rossi